SCIMP

Across TCGA pan-cancer cohorts, SCIMP mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SCIMP data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SCIMP mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SCIMP expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

GBM, LUAD, and LSCC are the cancer types where SCIMP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.223	0.578	.004	22	view →
LUAD	DFS	Quartile	II,III,IV	0.767	0.259	.014	16	view →
LSCC	OS	Median	All	0.993	0.743	.006	15	view →
PDAC	DFS	Median	All	0.675	0.356	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SCIMP–GBM (OS)

Open the GBM breakdown →